Hallifax D - Search Results

1

Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view.

Hallifax D, Foster JA, Houston JB. Hallifax D, et al. Pharm Res. 2010 Oct;27(10):2150-61. doi: 10.1007/s11095-010-0218-3. Epub 2010 Jul 27. Pharm Res. 2010. PMID: 20661765

2

Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes.

Jones HM, Hallifax D, Houston JB. Jones HM, et al. Among authors: hallifax d. Drug Metab Dispos. 2004 May;32(5):572-80. doi: 10.1124/dmd.32.5.572. Drug Metab Dispos. 2004. PMID: 15100181

3

Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.

Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G. Collett A, et al. Among authors: hallifax d. Pharm Res. 2004 May;21(5):819-26. doi: 10.1023/b:pham.0000026434.82855.69. Pharm Res. 2004. PMID: 15180340

4

Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.

Galetin A, Brown C, Hallifax D, Ito K, Houston JB. Galetin A, et al. Among authors: hallifax d. Drug Metab Dispos. 2004 Dec;32(12):1411-20. doi: 10.1124/dmd.104.000844. Epub 2004 Sep 1. Drug Metab Dispos. 2004. PMID: 15342470

5

CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.

Galetin A, Ito K, Hallifax D, Houston JB. Galetin A, et al. Among authors: hallifax d. J Pharmacol Exp Ther. 2005 Jul;314(1):180-90. doi: 10.1124/jpet.104.082826. Epub 2005 Mar 22. J Pharmacol Exp Ther. 2005. PMID: 15784650

6

Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm.

Ito K, Hallifax D, Obach RS, Houston JB. Ito K, et al. Among authors: hallifax d. Drug Metab Dispos. 2005 Jun;33(6):837-44. doi: 10.1124/dmd.104.003715. Drug Metab Dispos. 2005. PMID: 15897600

7

Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines.

Hallifax D, Rawden HC, Hakooz N, Houston JB. Hallifax D, et al. Drug Metab Dispos. 2005 Dec;33(12):1852-8. doi: 10.1124/dmd.105.005389. Epub 2005 Sep 20. Drug Metab Dispos. 2005. PMID: 16174807

8

Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans.

Rawden HC, Carlile DJ, Tindall A, Hallifax D, Galetin A, Ito K, Houston JB. Rawden HC, et al. Among authors: hallifax d. Xenobiotica. 2005 Jun;35(6):603-25. doi: 10.1080/00498250500162870. Xenobiotica. 2005. PMID: 16192111

9

Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance.

Hallifax D, Houston JB. Hallifax D, et al. Drug Metab Dispos. 2006 Nov;34(11):1829-36. doi: 10.1124/dmd.106.010413. Epub 2006 Aug 1. Drug Metab Dispos. 2006. PMID: 16882765

10

Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.

Brown HS, Galetin A, Hallifax D, Houston JB. Brown HS, et al. Among authors: hallifax d. Clin Pharmacokinet. 2006;45(10):1035-50. doi: 10.2165/00003088-200645100-00006. Clin Pharmacokinet. 2006. PMID: 16984215

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results